|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C12N 15/113 | (2010.01) |
| (11) | Number of the document | 4136092 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21895589.6 |
| Date of filing the European patent application | 2021-11-18 | |
| (97) | Date of publication of the European application | 2023-02-22 |
| (45) | Date of publication and mention of the grant of the patent | 2024-07-31 |
| (46) | Date of publication of the claims translation | 2024-09-25 |
| (86) | Number | PCT/US2021/059896 |
| Date | 2021-11-18 |
| (87) | Number | WO 2022/109139 |
| Date | 2022-05-27 |
| (30) | Number | Date | Country code |
| 202063115499 P | 2020-11-18 | US | |
| 202163232109 P | 2021-08-11 | US |
| (72) |
MULLICK, Adam , US
FREIER, Susan, M. , US
|
| (73) |
Ionis Pharmaceuticals, Inc. ,
2855 Gazelle Court, Carlsbad, CA 92010,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui |
| COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION |
| Payment date | Validity (years) | Amount | |
| 2024-10-21 | 4 | 92.00 EUR |
| 2025-11-18 |